[PDF] Top 20 A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
Has 10000 "A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma" found on our website. Below are the top 20 most common "A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma".
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
... of lenalidomide (Bartlett et al ...of lenalidomide was completed at Dana-Farber Cancer Institute (Richardson et al ...of lenalidomide was evaluated in 27 patients (median age 57 years; range, 40–71 ... See full document
8
A PROSPECTIVE COMPARATIVE STUDY OF SAFETY OF LENALIDOMIDE PLUS DEXAMETHASONE COMBINATION THERAPY VERSUS VAD (VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE) REGIMEN IN THE TREATMENT OF MULTIPLE MYELOMA
... Background: Lenalidomide plus Dexamethasone (Len-Dex) and VAD (Vincristine, Doxorubicin and Dexamethasone) regimen are the two common drug therapies involved in the treatment of ... See full document
8
Original Article Combination therapy with lenalidomide and dexamethasone for multiple myeloma: a meta-analysis of phase III randomized controlled trials
... this combination as salvage ther- apy for the treatment of relapsed/refractory MM ...receiving lenalidomide plus dexamethasone have a sig- nificantly longer overall survival, time to best ... See full document
9
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
... Continuous treatment with KRd might have been even more effica- cious in patients with high-risk ...prolonged treatment duration, is associ- ated with improved OS in newly diagnosed MM patients ... See full document
9
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
... Abstract: Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma ...and lenalidomide has dramatically improved the clinical outcome of MM ... See full document
8
Multiple myeloma presenting with high output heart failure and improving with anti angiogenesis therapy: two case reports and a review of the literature
... with multiple myeloma were evaluated for volume ...with multiple myeloma and volume ...on dexamethasone plus lenalidomide and thalidomide, ... See full document
6
Novel agents in the treatment of multiple myeloma: a review about the future
... and lenalidomide, prompting the design of a phase 1/2a trial investigating indatuximab-lenalidomide-dexamethasone among re- lapsed/refractory patients ...prior lenalidomide exposure and 50 % ... See full document
20
Follow Up Study of a Multiple Myeloma Patient Successfully Treated with Clarithromycin (CAM), Low Dose Lenalidomide and Low Dose Dexamethasone: Significance and Possible Mechanism of Action of CAM as an Add On Therapy
... the treatment (Figure ...the treatment was interrupted for 3 months because of ...the treatment, IgA gradually started to increase up to 946 ... See full document
12
<p>Carfilzomib for relapsed and refractory multiple myeloma</p>
... of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed refractory ...without dexamethasone, and in combination with ... See full document
13
Panobinostat for the treatment of multiple myeloma: the evidence to date
... in multiple myeloma to date, enrolling 768 patients. The combination of panobin- ostat, bortezomib, and dexamethasone was compared to bortezomib and dexamethasone alone in patients with ... See full document
8
Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma
... Results: In this study, a hapten of LND (N-glutaryl-LND) was synthesized by introducing the glutaryl moiety, as a spacer, into the primary aromatic amine site of the LND molecular structure. The structure of the hapten ... See full document
9
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
... Abstract: Multiple myeloma is a very heterogeneous disease with variable ...The combination of pomalidomide (POM) and dexamethasone is safe and effec- tive in relapsed and refractory patients, ... See full document
10
Front line treatment of elderly multiple myeloma in the era of novel agents
... high-dose dexamethasone regimen and thalidomide dosing was, up to 400 ...and dexamethasone used likely con- tributed to a higher mortality rate in Thal/Dex-treated patients during the first year of study, ... See full document
12
Carfilzomib boosted combination therapy for relapsed multiple myeloma
... bendamustine lenalidomide dexamethasone; CR, complete remission; Dara, daratumumab; dex, dexamethasone; DRd, daratumumab lenalidomide dexamethasone; ERd, elotuzumab lenalidomide ... See full document
13
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
... in combination therapy in the rrMM patients who had received at least two prior lines of ...This review focuses on the pharmacology and pharmacokinetic profile of PAN and clini- cal evidence to date, and ... See full document
11
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
... the combination of lenalidomide and dexamethasone plus oral ixazomib given twice weekly to newly diagnosed MM ...of lenalidomide on days 1–14, and dexamethasone (20 mg cycles 1–8, 10 mg ... See full document
8
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
... In a subgroup analysis comparing outcomes in patients with prior autologous SCT and no prior autologous SCT, there were no significant differences in ORR (63% vs 55%, respectively) or CR rate (13% vs 16%; P = 0.12). ... See full document
31
Download Download PDF
... studies, lenalidomide was ap- proved by the US FDA in June and by the Euro- pean Medicines Agency in June for use in combi- nation with dexamethasone in the treatment of MM in patients who ... See full document
8
Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
... Abstract: Treatment options for patients with multiple myeloma (MM) have increased during the past ...which combination strategies will provide the optimal response for any given ...refractory ... See full document
8
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
... that lenalidomide-dexamethasone was more effective in terms of response, TTP, PFS, and OS in patients who had one prior therapy when compared to those who had two or more earlier therapies, indicating that ... See full document
16
Related subjects